GILEAD SCIENCES, INC.·4

May 4, 4:22 PM ET

WELTERS ANTHONY 4

Research Summary

AI-generated summary

Updated

Gilead (GILD) Director Anthony Welters Receives Award

What Happened

  • Anthony Welters, a director of Gilead Sciences (GILD), acquired equity awards on April 30, 2026: 1,146 restricted stock units (RSUs) and a derivative award covering 4,884 shares. Both entries show $0.00 per share on the Form 4 (awards/grants).
  • The RSUs vested immediately on grant (see footnote F1). The 4,884-share derivative reflects a stock option award for which 100% of the shares vested immediately (see footnote F2). No sale or exercise of shares was reported.

Key Details

  • Transaction date: 2026-04-30; Form 4 filed 2026-05-04 (timely filed).
  • Price reported: $0.00 per share (award/grant).
  • Shares acquired: 1,146 RSUs (acquired) and 4,884 derivative-option shares (acquired as a grant).
  • Shares owned after transaction: not specified in the filing.
  • Footnotes: F1 — RSUs represent a contingent right to one share each and vested immediately. F2 — 100% of the stock option shares vested immediately upon grant.
  • Transaction code: A = Award/Grant. No P (purchase), S (sale), or M (exercise into shares) reported.

Context

  • These are compensation awards/vesting events, not open-market purchases or sales. Derivative entry indicates a stock-option grant that vested immediately; it does not indicate an exercise or sale of underlying shares unless separately reported.
  • Awards and immediate vesting are common for board compensation and do not by themselves indicate insider buying or selling intent.